

Subject Index

- A**
- abciximab, 1379
- ACC staff, 1401
- ACC/AHA guidelines
- for implantation of cardiac pacemakers and antiarrhythmic devices, 1368
 - for the management of patients with acute myocardial infarction, 1332, 1337. *See also* Myocardial infarction
- ACC/AHA statement "Guidelines for the Early Management of Patients with Acute Myocardial Infarction," 1336-1337
- Acid-base disturbances in ventricular fibrillation, 1364
- ACLS, 1337
- ACT, 1379
- Action plan, 1338
- Activity levels
- in hospital, 1354-1355
 - prior, return to, 1400t, 1400-1401
- Acute coronary syndrome, 1340, 1373
- identification of patient with, 1357
- Acute Infarction Ramipril Efficacy trial. *See* AIRE trial
- Acute myocardial infarction. *See* Myocardial infarction
- Adenosine, 1386
- Admitting orders, 1354, 1355t
- Adverse events
- monitoring for, 1354
 - protection against, 1354
 - PTCA effects on, 1350
 - treatment of, in hospital, 1356
- Afterload
- increasing of, 1360
 - reduction of, 1359, 1362, 1372
- Afterload-reducing agents, 1335
- Age, 1349
- atrial fibrillation incidence and, 1363
 - mortality rates related to, thrombolytic therapy effects on, 1348
 - Valsalva maneuver and, 1354, 1355
- Agitation, 1356
- AHA, 1399
- staff, 1401
 - Step I diet, 1395
 - step II diet, 1395
- AHA statement, "Aspirin as a Therapeutic Agent in Cardiovascular Disease," 1373
- Air travel, 1401
- AIRE (Acute Infarction Ramipril Efficacy) trial, 1397
- Alteplase, 1334, 1349, 1379, 1382
- combined with
 - aspirin, 1344
 - heparin, 1376, 1377, 1378, 1379
 - streptokinase, 1376
 - compared with
 - aspirin and heparin, 1352-1353
 - other thrombolytic agents, 1376
 - PTCA, 1350, 1351
 - dosing regimen for, 1375
 - efficacy in acute myocardial infarction, 1375
 - in ST-segment depression, effect on mortality rates, 1353
- American College of Cardiology. *See* ACC; ACC/AHA
- American College of Chest Physicians (ACCP), 1373
- American Fertility Society, 1399
- American Heart Association. *See* ACC/AHA; AHA
- Amiodarone, 1335, 1364
- pharmacology, 1381
 - for secondary prevention, 1399
 - for ventricular fibrillation, 1365
 - for ventricular tachycardia, 1364, 1365
- Amrinone, 1385, 1385t
- Analgesia, 1333, 1334, 1335, 1343. *See also* specific agent
- in hospital, 1355-1356
- Aneurysm, left ventricular, 1371
- Angina pectoris, 1345, 1359, 1387. *See also* Chest discomfort
- post-MI, refractory, intra-aortic balloon counterpulsation in, 1362
 - unstable, 1354
 - abciximab in treatment of, 1379
 - heparin for, 1380
 - in ST-segment depression, 1353
 - thrombolytic therapy in, 1352-1353
 - without ST-segment elevation, 1352
- Angiography, 1393
- in coronary artery disease, 1370
 - early
 - in non-ST-segment elevation or bundle branch block, 1352-1354
 - in ST-segment elevation or bundle branch block, 1351
 - after myocardial infarction, 1392
 - in nondiagnostic ECG changes, 1353
 - in survivor of myocardial infarction not receiving thrombolytic therapy, 1392
 - after thrombolytic therapy, 1392
 - use after first 24 hours, 1334-1335
- Angioplasty, percutaneous transluminal coronary (PTCA), 1335, 1337, 1359, 1378, 1401
- for accelerated idioventricular rhythm, 1365
 - adjuvant, after failed thrombolytic therapy, 1393
 - for cardiogenic shock, 1360
 - effect on clinical outcome, 1353
 - failed, coronary artery bypass graft surgery after, 1369
 - heparin with, 1334
 - with intra-aortic balloon pump, 1363
 - in left ventricular dysfunction, 1359
 - possible, after myocardial infarction, 1392
 - primary, 1333, 1340
 - applicability of, 1351
 - heparin use in, 1379
 - recommendations, 1348-1351
 - in right ventricular ischemia/infarction, 1361
 - results of, 1351
 - after thrombolytic therapy, 1392, 1393-1395
 - use rates, 1377
- Angiotensin-converting enzyme (ACE) inhibitors, 1335, 1337, 1372. *See also* specific agent
- contraindications to, 1383
 - dosage, 1383
 - recommendations, 1382-1383
 - for secondary prevention, 1397
- use
- after first 24 hours, 1334
 - during first 24 hours, 1334
- Anistreplase
- compared with other thrombolytic agents, 1376
 - efficacy in acute myocardial infarction, 1375
 - reuse of, 1376
 - use of heparin with, 1377-1378
- Anterior myocardial infarction
- large, 1334
 - thrombolytic therapy for, 1346
- Antiarrhythmic agents, 1380. *See also* specific agent; specific type of agent
- amiodarone, 1381
 - for atrial fibrillation, 1364
 - β -adrenoceptor blockers, 1381
 - bretylum, 1380-1381
 - lidocaine, 1380
 - procainamide, 1381
 - prophylactic, 1334, 1356
 - for ventricular fibrillation, 1365
 - for secondary prevention, 1399
- Anticoagulation. *See also*
- Antithrombotics/anticoagulants; specific agent
 - end point, 1373
- Anti-inflammatory drugs, nonsteroidal, 1359
- Anti-ischemic interventions, 1343
- Antioxidants, for secondary prevention, 1398
- Antiplatelet agents, 1344, 1373-1374, 1396. *See also* specific agent
- Antithrombin III (ATIII), 1378
- Antithrombotics/anticoagulants, 1335, 1358. *See also* specific agent
- heparin, 1377-1380
 - hirudin, 1380
 - for secondary prevention, 1398
- Anxiety, 1334
- decrease in, 1356
 - sympathetic drive and, 1355
- Anxiolytics, 1354, 1355-1356
- for nicotine withdrawal, 1356
- APSAC, comparison with other thrombolytic agents, 1375, 1375t
- aPTT testing, 1377, 1378
- Arrhythmias. *See also* Antiarrhythmic Agents; Rhythm disturbances
- detection of, 1354. *See also* Electrocardiography
 - fatal, 1337
 - mortality rates associated with, digitalis effects on, 1386
 - reperfusion, 1365
 - ventricular, 1354
 - assessment of, 1391
 - classification of, 1365
 - procainamide for, 1381
- Arterial monitoring, invasive, 1354
- Arterial pressure, in left ventricular dysfunction, 1359
- Aspirin, 1333, 1335, 1352, 1353, 1354, 1373, 1377, 1380
- for chest discomfort, 1335, 1358
 - combined with
 - streptokinase, 1375
 - thrombolytic agents, 1376
 - compared with alteplase and heparin, 1352-1353

- contraindications to, 1344
- mechanism of action, 1373
- prehospital use of, 1338
- in prevention of thrombotic complications of atherosclerosis, 1374
- recommendations for, 1344
- risk of hemorrhagic stroke with, 1734
- for secondary prevention, long-term use of, 1396-1397, 1398
- side effects and dosage, 1374
- suppositories, 1344
- use of
 - after first 24 hours, 1334
 - during first 24 hours, 1334
- Asystole. *See* Ventricular asystole
- Atenolol, 1363, 1381, 1382
 - for ventricular fibrillation prophylaxis, 1365
- Atherosclerosis
 - nitrate effects on, 1372
 - progression of, repeat coronary artery bypass graft surgery for, 1369
 - in saphenous vein grafts, 1395
 - thrombotic complications of, prevention of, aspirin in, 1373-1374
- ATRAMI (Autonomic Tone and Reflexes after Myocardial Infarction), 1391
- Atrial fibrillation
 - incidence of, 1363
 - in right ventricular infarction and dysfunction, 1360, 1361
 - in right ventricular ischemia, 1361
 - transient, 1364
 - treatment of, 1335
 - recommendations for, 1363-1364
- Atrial pressure, in right ventricular ischemia, 1360
- Atrioventricular (AV) block
 - atropine for, 1344
 - pacing for, 1367
 - prognosis of, 1366
 - treatment of, 1335
- Atrioventricular (AV) synchrony, 1368
 - in right ventricular ischemia/infarction, 1361, 1361t
- Atropine, 1334, 1335, 1356
 - for atrioventricular block, sinus bradycardia, or ventricular asystole, 1344
 - for bradyarrhythmias and heart block, 1366-1367
 - recommendations, 1344, 1345
 - side effects of, 1345
- Autonomic Tone and Reflexes after Myocardial Infarction. *See* ATRAMI
- B**
- Balloon flotation right-heart catheter monitoring, 1361-1362
- Baroreflex
 - sensitivity, sudden cardiac death risk and, 1391
 - stimulation, abnormal, 1335
- Bed rest, 1354
 - duration of, 1354
- β -adrenergic blocking agents, 1335, 1337, 1352, 1353, 1380, 1383. *See also* specific agent
 - adverse effects of, 1397
 - for atrial fibrillation, 1363, 1364
 - contraindications to, 1381, 1382
 - description of, 1381
 - diltiazem use with, 1384
 - long-term therapy, for secondary prevention, 1397-1398
 - nitroglycerin use with, 1372
 - recommendations for early therapy, 1381-1382
 - use
 - after first 24 hours, 1335
 - during first 24 hours, 1334
 - for ventricular fibrillation prophylaxis, 1365
 - for ventricular tachycardia, 1365
- Beta carotene, 1398
- Bezold-Jarish reflex, 1366
- Bile acid sequestrants, 1396
- Blood flow
 - collateral, 1359
 - effect of increased perfusion pressure on, 1362-1363
 - nitrate effects on, 1372
 - PTCA effects on, 1392
 - compared with thrombolytic therapy, 1350
 - reestablishment of, with thrombolytic therapy, 1374, 1375
- Blood pressure, 1333, 1338. *See also* Hypertension; Hypotension
 - effect of caffeine on, 1355
 - in left ventricular dysfunction, 1359
 - monitoring of, in hospital, 1354
- Blood specimens, 1357
- Bradyarrhythmias
 - background, epidemiology, and importance of, 1366
 - prognosis of, 1366
 - treatment of, 1366-1368
- Bradycardia, 1343. *See also* Sinus bradycardia
 - nitroglycerin-related, 1372
- Breathing difficulties, 1338
- Bretylium
 - dosage for, 1381
 - pharmacology, 1381
 - for ventricular fibrillation, 1365
- Bronchoplastic disease, 1383
- Bundle branch block (BBB), 1335, 1366, 1377
 - diagnostic and treatment measures for, 1350t
 - early angiography in, 1351
 - left, 1334
 - symptoms of, 1333
 - management of, 1345f, 1346
 - pacing for, 1367, 1368
 - thrombolytic therapy for, 1346, 1347, 1347f
- C**
- Caffeine intake, 1355
- Calcium channel blocking agents, 1353, 1381, 1399.
 - See also* specific agent
 - for atrial fibrillation, 1364
 - diltiazem, 1363, 1383, 1384
 - during first 24 hours, 1334
 - nifedipine, 1383
 - recommendations, 1383
 - for secondary prevention, 1398
 - summary of, 1384
 - verapamil, 1363, 1383-1384
- CAMIAT (Canadian Amiodarone Myocardial Infarction Arrhythmia Trial), 1400
- Canadian Amiodarone Myocardial Infarction Arrhythmia Trial. *See* CAMIAT
- Captopril, 1373, 1382, 1383
 - for secondary prevention, 1397
- Cardiac arrest
 - mortality rates for, 1369
 - prehospital treatment of, survival rate related to, 1338, 1339
- Cardiac catheterization, 1338, 1340, 1386
 - in mechanical defects, 1370
 - in non-ST-segment elevation cohort, 1353
 - following thrombolytic therapy, 1393
- Cardiac events, recurrence of, 1337, 1400
- Cardiac output
 - in left ventricular dysfunction, 1359
 - low, 1344, 1385
 - in right ventricular ischemia/infarction, 1361
 - thermodilution, 1370
- Cardiac rehabilitation, 1335, 1399-1400
 - exercise testing and, 1387
- Cardiac rupture
 - recurrent chest pain from, 1359
 - risk factors for, 1359
- Cardiac tamponade, 1358, 1359
- Cardiac transplantation, 1371
- Cardiogenic shock. *See* Shock, cardiogenic
- Cardiologists, interventional
 - corridor of outcomes and, 1350
 - PTCA performed by, 1350
- Cardiopulmonary resuscitation (CPR), 1337, 1356
 - patients undergoing, coronary artery bypass graft surgery for, 1369
- Cardiovascular disease
 - antioxidants for, 1398
 - after bed rest, 1354
 - magnesium and, 1384
- Cardioversion, 1335
 - for atrial fibrillation, 1363
 - for ventricular tachycardia, 1364
- CARE (Cholesterol and Recurrent Events) trial, 1395
- CAST substudy, 1391
- Catecholamines, inotropic agents, 1385
- Catheter, 1335
 - balloon flotation, 1361-1362, 1370
 - central, 1362
 - intra-arterial, 1362
- Catheterization. *See* Cardiac catheterization
- Chest discomfort, 1338. *See also* Angina pectoris
 - checklist for, 1339, 1339t
 - ischemic-type, 1338-1339, 1340
 - sympathetic drive and, 1355
 - referral of, 1338
 - treatment of, 1335
- Cholesterol. *See* Lipids, Lipoprotein
- Cholesterol and Recurrent Events trial. *See* CARE trial
- Chronic obstructive airway disease, 1343
- Cimetidine, 1356, 1374
- Circulatory support devices, for failing heart, 1371
- Class I conditions, 1336
 - angiotensin-converting enzyme inhibitors in, 1382
 - atrial fibrillation in, 1363
 - atropine for, 1344, 1366
 - balloon flotation right-heart catheter monitoring in, 1361
 - β -adrenergic blocking agents for, 1381
 - emergency or urgent coronary artery bypass graft surgery for, 1351
 - heparin in, 1377
 - hospital management of, early, general measures, 1354
 - initial recognition and management in emergency department, 1340
 - intra-aortic balloon counterpulsation in, 1362
 - intra-arterial pressure monitoring in, 1362
 - invasive evaluation of, 1392
 - management of recurrent chest pain in, 1358
 - noninvasive evaluation of, 1386
 - non-ST segment elevation in, risk stratification and management, 1352
 - oxygen, nitroglycerin, and aspirin for, 1342, 1343
 - pacing for, 1367, 1368
 - prehospital issues, 1337
 - primary percutaneous transluminal coronary angioplasty in, 1350
 - secondary prevention in
 - β -adrenoceptor blocking agents for, 1397
 - long-term anticoagulation, 1398
 - thrombolytic therapy for, 1346
 - ventricular tachycardia/fibrillation in, 1364

- Class II conditions, 1336
- Class IIa conditions, 1336
- angiotensin-converting enzyme inhibitors in, 1382
 - atrial fibrillation in, 1363
 - atropine for, 1344
 - balloon flotation right-heart catheter monitoring in, 1361
 - calcium channel blockers for, 1383
 - early angiography in, 1351
 - emergency or urgent coronary artery bypass graft surgery for, 1351
 - heparin in, 1377
 - intra-aortic balloon counterpulsation in, 1362
 - intra-arterial pressure monitoring in, 1362
 - invasive evaluation of, 1392
 - magnesium for, 1384
 - management of lipids in, 1395
 - management of recurrent chest pain in, 1358
 - noninvasive evaluation of, 1386
 - non-ST segment elevation in, risk stratification and management, 1352
 - oxygen, nitroglycerin, and aspirin for, 1342, 1343
 - pacing for, 1367, 1368
 - prehospital issues, 1337
 - primary percutaneous transluminal coronary angioplasty in, 1350
 - secondary prevention in
 - β -adrenoceptor blocking agents for, 1397
 - estrogen replacement therapy, 1399
 - long-term anticoagulation, 1398
 - thrombolytic therapy for, 1346
 - ventricular tachycardia/fibrillation in, 1364
- Class IIb conditions, 1336
- angiotensin-converting enzyme inhibitors in, 1382
 - atropine for, 1344
 - β -adrenergic blocking agents for, 1381
 - calcium channel blockers for, 1383
 - early angiography in, 1351
 - emergency or urgent coronary artery bypass graft surgery for, 1351
 - heparin in, 1377
 - hospital management of, early, general measures, 1354
 - intra-aortic balloon counterpulsation in, 1362
 - intra-arterial pressure monitoring in, 1362
 - invasive evaluation of, 1392
 - magnesium for, 1384
 - management of lipids in, 1395
 - management of recurrent chest pain in, 1358
 - non-ST segment elevation in, risk stratification and management, 1352
 - oxygen, nitroglycerin, and aspirin for, 1342, 1343, 1344
 - pacing for, 1367, 1368
 - prehospital issues, 1337
 - primary percutaneous transluminal coronary angioplasty in, 1350
 - secondary prevention in, long-term anticoagulation, 1398
 - thrombolytic therapy for, 1346, 1347
 - ventricular arrhythmia assessment, 1391
 - ventricular tachycardia/fibrillation in, 1364
- Class III conditions, 1336
- atropine for, 1344, 1366
 - balloon flotation right-heart catheter monitoring in, 1361
 - β -adrenergic blocking agents for, 1381
 - calcium channel blockers for, 1383
 - early angiography in, 1351
 - emergency or urgent coronary artery bypass graft surgery for, 1351
 - heparin in, 1377-1378
 - hospital management of, early, general measures, 1354
 - intra-arterial pressure monitoring in, 1362
 - invasive evaluation of, 1392
 - noninvasive evaluation of, 1386
 - oxygen, nitroglycerin, and aspirin for, 1342, 1343
 - pacing for, 1367, 1368
 - prehospital issues, 1337
 - primary percutaneous transluminal coronary angioplasty in, 1350
 - secondary prevention in, long-term anticoagulation, 1398
 - thrombolytic therapy for, 1346, 1347
 - ventricular arrhythmia assessment, 1391
 - ventricular tachycardia/fibrillation in, 1364
- hospital management of, early, general measures, 1354
- intra-arterial pressure monitoring in, 1362
- invasive evaluation of, 1392, 1393
- noninvasive evaluation of, 1386
- oxygen, nitroglycerin, and aspirin for, 1343
- pacing for, 1367, 1368
- secondary prevention in, β -adrenoceptor blocking agents for, 1397
- thrombolytic therapy for, 1347
- ventricular tachycardia/fibrillation in, 1364
- Clinical end-point, effect of intra-aortic balloon pumping on, 1363
- Clinical variables
- assessment of, 1357, 1357f
 - mortality risk and, 1356, 1357f
- Clonidine, 1396
- Coagulation, heparin effects on, 1378
- Coagulation cascade, activation of, 1377
- Coagulation system, breakdown of, 1378
- Collateral blood flow, lack of, 1359
- Commode privileges, 1354, 1355
- Complications, freedom from, 1356
- Computed tomography, single-photon emission (SPECT), 1388
- Computer algorithms, 1354
- Computer-aided diagnostic aids, 1340
- Conduction
- delay, intraventricular, 1366
 - disturbances, 1368
- Confidence interval, 1339
- Congestive heart failure (CHF), 1368, 1380
- ACE inhibitors for, 1334, 1382
 - incidence of, magnesium effects on, 1384
 - management of, 1335
 - in hospital, 1359-1362
 - mechanical support for, 1371
 - nitrites in, 1372
 - in pericarditis, 1358
- CONSENSUS (Cooperative New Scandinavian Enalapril Survival II) Study, 1382
- Contractility, 1385
- Cooperative New Scandinavian Enalapril Survival II Study. *See* CONSENSUS study
- Coronary artery bypass graft (CABG) surgery, 1337
- clinical situations leading to, 1368-1370
 - emergency, 1333, 1350, 1351
 - recommendations for, 1351-1352
 - in left ventricular dysfunction, 1359
 - minimum operative caseload, 1371
 - myocardial infarction during, 1395
 - use rates, 1377
 - in ventricular septal defect, 1371
 - volume of, relation to outcome, 1371
- Coronary artery disease
- blood lipid profile in, 1396
 - myocardial infarction incidence related to, 1395
- Coronary artery patency, thrombolytic therapy and, 1392, 1393
- Coronary care unit (CCU)
- admission to, 1340
 - alternatives to, 1356
 - electrocardiography in, 1354
 - intra-arterial pressure monitoring in, 1362
 - length of stay in, reduction of, 1356
 - temporary pacemaker care in, 1368
 - transfer from, 1357
- Coronary flow. *See* Blood flow
- Coronary heart disease. *See* Coronary artery disease
- Coronary occlusion, 1360
- revascularization in, 1353
 - thrombus in, 1376
 - total, 1352
- treatment of, 1359-1360
- Coronary perfusion
- effect of heparin on, 1378
 - in right ventricular infarction and dysfunction, 1360
- "Coronary precautions," 1354
- Coronary reocclusion, 1363
- "Corridor of outcomes," 1350
- Corticosteroids, for chest discomfort, 1358
- Costs
- PTCA compared with thrombolytic therapy, 1351
 - reduction of, 1356, 1357
- Counterpulsation, intra-aortic balloon
- in left ventricular dysfunction, 1359
 - recommendations for, 1362-1363
- Countershock, for ventricular fibrillation, 1335
- Couplets, 1364
- Creatine kinase (CK), 1334, 1356, 1395
- Creatine kinase-MB (CK-MB), 1340, 1341
- in pericarditis, 1358
 - in reinfarction, 1358
- D**
- DANAMI (Danish Acute Myocardial Infarction) Trial, 1394
- Danish Acute Myocardial Infarction Trial. *See* DANAMI Trial
- Defibrillation, defibrillator, 1334, 1337, 1356
- automatic external (AED), 1339
 - prehospital, 1338-1339
 - for ventricular fibrillation, 1365
- Delirium, 1356
- Demographic variables, assessment of, 1357, 1357f
- Depression, decrease in, 1356
- Desirudin, 1380
- Dextrose, 1381
- Diabetes, 1348
- thrombolytic therapy and, 1346
- Diagnosis, 1357
- time required for, 1338
- Diaphoresis, 1338
- Diastole, β -adrenoceptor effects on, 1381
- Diastolic dysfunction, right ventricular, 1360
- Diazepam, 1356
- Diet, 1335
- for management of lipids, 1395
- DIG. *See* Digitalis Investigator Group
- Digitalis, 1335, 1385
- in atrial fibrillation, 1363
 - pharmacology, 1386
- Digitalis Investigator Group (DIG), 1386
- Digoxin, 1363
- Dihydropyridines, use, during first 24 hours, 1334
- Diltiazem, 1383
- for atrial fibrillation, 1363
 - contraindications to, 1383
 - pharmacology, 1384
 - use, during first 24 hours, 1334
- Dipyridamole, 1344, 1386, 1388, 1389
- Discharge from hospital, preparation for, 1335
- invasive evaluation, 1392-1395
 - noninvasive evaluation of low risk patients, 1386-1391
 - secondary prevention, 1395-1399
- Diuretics, diuresis, 1335, 1359
- in right ventricular ischemia/infarction, 1361
- Dobutamine, 1385t, 1388, 1389
- Doom, impending, feeling of, 1338
- Dopamine, 1385, 1385t
- for hypotension, 1385
 - in left ventricular dysfunction, 1359
- Dressler syndrome, 1358
- Driving, 1401

DUCCS-1 study, 1378
Dutepase, 1376
Dyspnea, 1387

E

Echocardiography, echocardiogram
in cardiac rupture, 1359
in emergency department, 1346
exercise, 1335, 1390
for discharge from hospital, 1386
in pseudoaneurysm, 1359
resting, abnormalities in, 1386n
in right ventricular ischemia, 1360, 1361
role in preparation for discharge from hospital, 1388-1389
two-dimensional, 1340
Ectopy. *See* Ventricular ectopy
Education, 1338, 1399
patient, 1333
effect on emotional distress, 1355
Ejection fraction, 1389, 1391, 1392
ACE inhibitor effects on, 1334, 1397
in pericarditis, 1358
Elderly. *See also* Age
non-diagnostic ECG changes in, 1352
non-Q wave myocardial infarction in, 1352
percutaneous transluminal coronary angioplasty
in mortality rates, compared with
thrombolytic therapy, 1350
reperfusion therapy in, 1352
symptoms of acute myocardial infarction in, 1340
thrombolytic therapy for, 1346
effect on mortality rates, 1348
risk of stroke and, 1349
Electric shock, for ventricular
tachycardia/ventricular fibrillation, 1364,
1365
Electrical instability, 1335
"Electrical storm," 1365, 1381
Electrocardiography, electrocardiogram (ECG),
1340. *See also* Holter monitoring; specific
segment; specific wave
in CCU, 1354
effect of thrombolytic therapy on, 1345
exercise, 1387
interpretation of, errors in, 1340
nondiagnostic changes, 1340, 1352
effect of thrombolytic therapy in, 1353
mortality rates related to, 1353
normal, mortality rates rates in, 1352
prehospital, 1339
in recurrent chest pain, 1358
in right ventricular ischemia, 1360
signal-averaged, for ventricular arrhythmia
assessment, 1391
Electrolyte disturbances, in ventricular fibrillation,
1364
Electrophysiologic mechanisms, in myocardial
infarction, 1364
Embolic stroke, 1378
Embolization, in atrial fibrillation, 1363
Emergency department (ED), initial recognition
and management of acute myocardial
infarction in, 1333-1334, 1349, 1349t, 1350t
atropine in, 1344-1345
detection/quantitation and risk assessment,
1340-1342f
noninvasive imaging, 1345, 1346
recommendation, 1340
risk stratification and management of ST-
segment elevation/bundle branch block
cohort, 1345, 1345f, 1346
routine measures (oxygen, nitroglycerin, aspirin),
1342-1344

thrombolysis, 1346-1349
Emergency medical services (EMS) system, 1338-
1339
capabilities of, 1338-1339
early access to, 1338-1339
Emergency medical system personnel, 1333, 1339
Emergency medical technicians (EMTs), work of,
healthcare settings for, 1338-1339
EMIAT (European Myocardial Infarction
Amiodarone Trial), 1400
Enalapril, 1382, 1383
for secondary prevention, 1397
Enalaprilat, 1383
Endothelium-derived relaxing factor (EDRF), nitric
oxide, 1372
Epinephrine, 1334
for ventricular fibrillation, 1365
Estrogen replacement therapy (ERT), myocardial
infarction and, 1399
European Cooperative Study Group VI trial, 1394
European Myocardial Infarction Amiodarone Trial.
See EMIAT
Exercise, 1335
Exercise testing. *See also under* Echocardiography
for discharge from hospital, 1335, 1390
echocardiography, 1387
low-level, 1387
myocardial perfusion imaging, 1387, 1388
optimum time for performing, 1387
symptom-limiting, 1387
myocardial perfusion imaging, 1387, 1388

F

Factor V, 1378
Factor VII, 1378
Factor X, 1378
Factor Xa, 1379
Family members, care by, 1355-1356
Fascicular block, pacing for, 1368
Fibrates, 1396
Fibrillation. *See* Atrial fibrillation; Ventricular
fibrillation
Fibrin, 1377, 1393
Fibrin-specificity of thrombolytic agents, 1375
Fibrinogen, 1377
Fibrinogen degradation products, 1378
Fibrinolytic therapy. *See* Thrombolytic therapy
First International Study of Infarct Survival, 1382
First responders, 1338-1339
Fluid, 1354. *See also* Water
Free wall rupture, left ventricular, 1359
Furosemide, 1335, 1359

G

Gastric side effects, of aspirin, 1374
Gemfibrozil, 1395, 1396
Gender, 1348
GISSI (Gruppo Italiano per lo Studio della
Streptochinasi nell'infarto Miocardico)
study, 1352
GISSI-2, 1376, 1378
GISSI-3 trial, 1373, 1382, 1383
Global Utilization of Streptokinase and TPA for
Occluded Arteries trial. *See* GUSTO trial
Gruppo Italiano per lo Studio della Streptochinasi
nell'infarto Miocardico study. *See* GISSI
study
GUSTO (Global Utilization of Streptokinase and
TPA for Occluded Arteries) trial, 1334,
1363, 1369, 1376
GUSTO-I, 1378
GUSTO-IIb, 1351, 1380

H

Hand perfusion, 1362
Headache, nitroglycerin-related, 1372
Healthcare providers, local, involvement of, 1339
Heart block. *See also* Atrioventricular block;
Bundle branch block
background, epidemiology, and importance of,
1366
prognosis of, 1366
risk factors for, 1366
treatment of, 1366-1368
Heart failure. *See* Congestive heart failure
Heart rate, 1338, 1385
low, thrombolytic therapy and, 1346
nitrate effects on, 1372
variability, 1391
Helsinki Primary Prevention Trial, 1396
Hemodynamic compromise
in atrial fibrillation, 1363
emergency or urgent coronary artery bypass graft
surgery for, 1351
in left ventricular dysfunction, 1359
in right ventricular infarction and dysfunction,
1360
Hemodynamic monitoring
balloon flotation right-heart catheter monitoring,
1361-1362
intra-aortic balloon counterpulsation, 1362-1363
intra-arterial pressure monitoring, 1362
Hemorrhage, 1373
intracranial (ICH), 1380
intraplaque, 1374
risk of, aspirin and, 1374
thrombolytic therapy-related, 1375
intracranial (ICH), 1333, 1349, 1376
Heparin, 1334, 1353, 1358
as antithrombotic agent, 1379-1380
for atrial fibrillation, 1363
combined with thrombolytic agents, 1376
compared with alteplase and aspirin, 1352-1353
discontinuation of, 1379
dosing, in thrombolytic therapy, 1379
duration of therapy, 1379
interaction with nitroglycerin, 1373
low molecular weight, 1380
pharmacology, 1378
recommendations, 1377-1380
unfractionated, 1379
use
after first 24 hours, 1334, 1335
with PTCA, 1334
after thrombolytic therapy, 1334
Heparin-ATIII complex, 1378
High risk patient
in hospital identification and treatment of
for bradyarrhythmias and heart block, 1366-
1368
for heart failure and low-output syndrome,
1359-1362
intra-aortic balloon counterpulsation, 1362-
1363
intra-arterial pressure monitoring, 1362
for recurrent chest discomfort, 1358-1359
for rhythm disturbances, 1363-1368. *See also*
Rhythm disturbances
surgical interventions, 1368-1370
for ventricular tachycardia/ventricular
fibrillation, 1364-1366
prehospital identification of, 1338, 1339
Hirudin, 1379, 1380
History, 1340
HmG CoA reductase drugs, 1395n, 1396
Holter monitoring, 1399
for ischemia, 1390-1391

- for ventricular arrhythmia assessment, 1391
 - Home exercise training programs, 1400
 - Hospital, nearest, location of, 1338
 - Hospital management of acute myocardial infarction. *See also* Discharge from hospital case selection concerns, 1371
 - early, general measures, 1354-1356
 - first 24 hours, 1334
 - after first 24 hours, 1334-1335
 - identification and treatment of patient at high risk, 1358-1370
 - identification and treatment of patient at low risk, 1356-1357
 - of mechanical defects after acute myocardial infarction, 1370t, 1370-1371
 - minimum operative caseload, 1371
 - relation between volume of surgery and outcome, 1371
 - transplantation after acute myocardial infarction, 1371
 - visiting rules, 1356
 - Hospital stay, reduction of, 1355, 1356
 - Hypercholesterolemia, 1395
 - Hypertension
 - cardiac rupture in, 1359
 - nitrate effects on, 1372
 - thrombolytic therapy and, 1346, 1347, 1349
 - Hypertriglyceridemia, 1396
 - Hypokalemia, 1384
 - ventricular fibrillation risk and, 1365
 - Hypoperfusion, peripheral, 1344
 - Hypotension, 1339, 1348, 1354, 1385
 - atropine for, 1344
 - early sustained, absence of, 1356
 - exertional, 1387
 - intra-arterial pressure monitoring in, 1362
 - morphine-induced, 1355
 - nitroglycerin-related, 1343, 1361, 1372
 - in sinus bradycardia, 1366, 1367
 - thrombolytic therapy and, 1346
 - treatment of, 1335
 - Hypoxemia, 1372
 - correction of, 1343, 1344
- I**
- Ibuprofen, for chest discomfort, 1358
 - Identification of myocardial infarction, prehospital, 1333
 - Idioventricular rhythm, accelerated, 1364, 1365
 - Incomplete Infarction Trial of European Research Collaborators Evaluating Prognosis Post Thrombolysis trial. *See* INTERCEPT trial
 - Indomethacin, for chest discomfort, 1358
 - Infarct size
 - measurement of, 1390
 - in pericarditis, 1358
 - Inferior myocardial infarction
 - atropine for, 1344
 - right ventricular infarction accompanying, 1360
 - use of nitrates in, 1372
 - Inotropic agents, 1335, 1362, 1385-1386
 - classification of, 1385, 1385t
 - in right ventricular ischemia/infarction, 1361
 - INTERCEPT trial (Incomplete Infarction Trial of European Research Collaborators Evaluating Prognosis Post Thrombolysis), 1384
 - Internal jugular vein, for transvenous pacing, 1368
 - International Normalized Ratio (INR), for anticoagulants, 1398
 - International Study of Infarct Survival. *See under* ISIS
 - Interventonal therapy, in non-ST-segment elevation cohort, 1352-1354
 - Intra-aortic balloon pump (IABP), 1370
 - for failing heart, 1371
 - for ventricular tachyarrhythmias, 1369
 - Intra-arterial pressure monitoring, recommendations for, 1362
 - Intravascular volume, inadequate, 1361
 - Invasive evaluation, for preparation for discharge from hospital, 1392-1395
 - Ischemia, 1335, 1383. *See also* Myocardial ischemia exercise-induced, after thrombolytic therapy, 1394
 - incidence of, magnesium effects on, 1384
 - management of, in hospital, 1358-1359
 - persistent or recurrent, 1380
 - coronary artery bypass graft surgery for, 1369
 - emergency or urgent coronary artery bypass graft surgery for, 1351
 - intra-aortic balloon counterpulsation in, 1362-1363
 - PTCA for, compared with thrombolytic therapy, 1351
 - revascularization for, 1350
 - right ventricular, 1360. *See also* Right ventricular infarction and dysfunction
 - management of, 1361, 1361t
 - treatment of, 1345
 - unstable, 1362
- ISIS-2 (Second International Study of Infarct Survival), 1344, 1352, 1375
- ISIS-3, 1376, 1378
- ISIS-4, 1373, 1382, 1383, 1384-1385
- Isoproterenol, 1385, 1385t
- Isosorbide dinitrate (ISDN), pharmacokinetics and dosage, 1372
- Isosorbide mononitrate (ISMN), 1373
 - pharmacokinetics and dosage, 1372
- L**
- Laboratory tests, for confirmation of myocardial infarction, 1340, 1341. *See also* specific procedure
 - Late Assessment of Thrombolytic Efficacy Trial. *See* LATE Trial
 - LATE (Late Assessment of Thrombolytic Efficacy) Trial, 1347, 1353
 - Late potentials, 1335
 - sudden cardiac death and, 1391
 - Left subclavian vein, for transvenous pacing, 1368
 - Left ventricular dysfunction, 1391
 - coronary artery bypass graft surgery for, 1369, 1370
 - management of, 1359-1360
 - in right ventricular ischemia/infarction, 1361
 - Left ventricular function
 - assessment of, for discharge from hospital, 1389
 - effect of intra-aortic balloon pumping on, 1363
 - after thrombolytic therapy, 1393-1394
 - Left ventricular remodeling, nitroglycerin effects on, 1373
 - Leg elevation, 1344
 - Licenses, 1357
 - Lidocaine, 1335, 1356
 - dosage of, 1381
 - pharmacology of, 1381
 - for ventricular fibrillation, 1365
 - for prophylaxis, 1365
 - for ventricular tachycardia, 1364, 1365
 - Limb perfusion, 1362
 - LIMIT-2 (Second Leicester Intravenous Magnesium Intervention Trial) trial, 1384
 - Lipid(s), management of, for secondary prevention, 1395-1396
 - Lipoprotein
 - high-density (HDL), 1395, 1396
 - low-density (LDL), 1395
 - reduction of, 1335
 - Lisinopril, combined with nitrates, 1373
 - Loading conditions, changes in, during Valsalva maneuver, 1354
 - Long-term management, 1400
 - cardiac rehabilitation, 1400
 - return to prior level of activity, 1400t, 1400-1401
 - Low-risk patients
 - identification and treatment of, in hospital, 1356-1357
 - noninvasive evaluation of. *See* Noninvasive evaluation
- M**
- MAGIC (Magnesium in Coronary Disease) trial, 1385
 - Magnesium sulfate
 - background, 1384, 1385
 - recommendations, 1384
 - repletion of, 1365
 - use, after first 24 hours, 1334
 - Magnesium in Coronary Disease trial. *See* MAGIC trial
 - MDPIT (Multicenter Diltiazem Postinfarction Trial), 1384
 - Mechanical defects, after acute myocardial infarction, management of
 - acute mitral valve regurgitation, 1370-1371
 - diagnosis, 1370t, 1370-1371
 - left ventricular aneurysm, 1371
 - left ventricular free wall rupture, 1371
 - mechanical support of failing heart, 1371
 - surgery for, 1368
 - Medical care, seeking of, timing for, 1338
 - Medications. *See* Pharmacotherapy
 - Medroxy-progesterone, 1399
 - Meperidine, 1333, 1356
 - MET level, 1400t, 1401
 - Metoprolol, 1363, 1381
 - for secondary prevention, 1397
 - for ventricular fibrillation prophylaxis, 1365
 - Metoprolol in Acute Myocardial Infarction trial. *See* MIAMI trial
 - Mexiletine, 1356
 - MIAMI (Metoprolol in Acute Myocardial Infarction) trial, 1382
 - Milrinone, 1385, 1385t, 1386
 - Mitral valve
 - regurgitation, postinfarction, management of, 1371
 - emergency or urgent coronary artery bypass graft surgery for, 1351
 - replacement, 1370
 - Morphine, morphine sulfate, 1333, 1343
 - administration, in hospital, 1355-1356
 - adverse effects of, 1355
 - atropine combined with, 1344
 - side effects of, 1344
 - Mortality. *See also* Sudden cardiac death
 - predictors of, 1391
 - risks of, 1356, 1357f
 - Mortality rate, in acute myocardial infarction, 1337, 1350
 - angiotensin-converting enzyme inhibitors effect on, 1382-1383
 - aspirin effects on, 1344, 1396
 - atenolol effects on, 1382
 - cardiac arrest-related, 1369
 - in cardiogenic shock, 1359-1360
 - conduction disturbances and, 1368
 - coronary artery bypass graft surgery-related, 1369
 - digitalis effects on, 1386

- diltiazem effects on, 1384
exercise testing and, 1387
heart block and intraventricular conduction delay-related, 1366
heparin effects on, 1378
hospital staffing related to, 1357
left ventricular function and, 1389
magnesium effects on, 1384
nifedipine effects on, 1383
nitrate effects on, 1373
in nondiagnostic ECG changes, 1353
operative, in ventricular septal defect, 1371
periprocedural myocardial infarction-related, 1395
prehospital, 1333
PTCA and, compared with thrombolytic therapy, 1350, 1351
reduction in, 1337, 1387
simvastatin effects on, 1395
ST-segment elevation-related, 1340
in survivors of MI, predictors of, 1393
thrombolytic therapy effects on, 1333, 1346, 1347f, 1348, 1348t, 1375, 1376
time factor in, 1334
in ventricular fibrillation, 1365
verapamil effects on, 1384
volume of surgery and, 1371
- Multicenter Diltiazem Postinfarction Trial. *See* MDPIIT
- Murmur, 1370
- Myocardial damage, minimizing of, 1354
- Myocardial hibernation, assessment of, 1388-1389
- Myocardial infarction (MI)
complications of, recognition and management of, 1335
coronary artery bypass graft surgery for, elective, 1369
diagnosis of, 1340
timing for, 1356
evolving, coronary artery bypass graft surgery for, 1369
exclusion of, 1356, 1357
incidence of, 1333, 1337
reduction of. *See also* Secondary prevention management of
ACC/AHA guidelines for, 1332
in emergency department, 1333-1334
hospital. *See* Hospital management
long-term, 1335
prehospital issues, 1333
pathophysiology of, 1376
patients. *See* Patients
symptoms of, 1333, 1338
time-dependent process of, 1341
true, identification of patients with, 1340
- Myocardial ischemia
after first 24 hours, 1334
Holter monitoring for, 1390-1391
nitroglycerin-related, 1343
reduction of, 1364
treatment of, 1335
- Myocardial necrosis
biochemical markers of, assays for, 1341
serum markers of, 1346
- Myocardial perfusion imaging, 1390
exercise, 1387, 1388
for infarct size measurement, 1389-1390
- Myocardial protection, in acutely injured heart, coronary artery bypass graft surgery for 1370
- Myocardial viability, assessment of, 1389
- Myocyte, necrosis, serum cardiac markers of, 1334
- Myoglobin, 1341, 1342t, 1356
- N**
- Naloxone, 1355
- NAMIS (Nifedipine Angina Myocardial Infarction Study), 1383
- Narcotics, 1334
- Nasal prongs, 1343
- National Cholesterol Education Panel, 1396
- National Heart, Lung, and Blood Institute (NHLBI), 1337, 1385
- National Heart Attack Alert Program (NHAAP), 1337
- National Registry of Myocardial Infarction, 1376
- Nausea and vomiting, 1344
- Neck veins, in right ventricular ischemia, 1360, 1361
- Necrosis. *See* Myocardial necrosis
- NHLBI. *See* National Heart, Lung, and Blood Institute
- Niacin, 1395, 1395n
- Nicotine gum and patches, 1396
- Nicotine withdrawal, 1356
- Nicotinic acid, 1396
- Nifedipine, 1334
contraindications to, 1383
pharmacology, 1383
- Nifedipine Angina Myocardial Infarction Study. *See* NAMIS
- 911 system, 1338-1339
- Nitrates, 1353, 1380
clinical trials of, 1373
in right ventricular ischemia/infarction, 1361
tolerance to, 1372
- Nitric oxide, 1372
- Nitroglycerin, 1333, 1334, 1335, 1343, 1354, 1362
clinical trials of, 1373
contraindications to, 1343
intravenous, 1372
recommendations for, 1343
for left ventricular dysfunction, 1359
limitations and adverse effects, 1343, 1372-1373
mechanism of action, 1372
pharmacokinetics and dosage, 1372
prehospital use of, 1338
sublingual, 1343
titration of, 1372
transdermal, 1343
- Noninvasive evaluation
in emergency department, 1346
of low risk patient. *See also* Echocardiography
ambulatory electrocardiographic monitoring for ischemia, 1390-1391
assessment of ventricular arrhythmia, 1391
of left ventricular function, 1389
measurement of infarct size, 1389-1390
radionuclide testing for diagnosis of acute myocardial infarction, 1389
recommendations, 1386
role of echocardiography, 1388-1389
role of exercise testing, 1386-1388. *See also* Exercise testing
positive predictive value, 1390
- Non-Q wave myocardial infarction, 1345, 1354
heparin in, 1380
interventional therapy for, 1353
risk stratification and management in, 1352
- Norepinephrine, 1380, 1385, 1385t
for hypotension, 1385
in left ventricular dysfunction, 1359
- Norwegian Nifedipine Multicenter Trial, 1383
- O**
- Occlusion. *See* Coronary occlusion
- Open infarct-related artery, 1391
- Opiate therapy, 1344
- OSIRIS study, 1378
- Outcome, relation to volume of surgery, 1371
- Oximetry, 1354
- Oxygen
administration, in emergency department, 1342, 1344
consumption, effect of increased perfusion pressure on, 1362-1363
demand and supply, 1354, 1355
 β -adrenoreceptor effects on, 1381
myocardial, 1372
in right ventricular infarction and dysfunction, 1360
saturation, 1370
monitoring of, 1343, 1354. *See also* Oximetry
- P**
- Pacemaker, 1356
- Pacing, 1334
AV (dual chamber), 1368
for bradyarrhythmias and heart block, 1366, 1367-1368
after first 24 hours, 1335
permanent, 1368
in right ventricular ischemia/infarction, 1361
transcutaneous, 1367
transvenous, temporary, 1367-1368
ventricular (single chamber), 1368
- Pain. *See also* Angina pectoris; Chest discomfort of acute myocardial infarction, 1343
- PAMI (Primary Angioplasty in Myocardial Infarction) investigators, 1350
- PAMI-II study, 1400
- Parasympathetic tone, influence on heart, 1391
- Patency, 1334
- Patient(s)
classification of, 1337
with myocardial infarction, differences in, 1336
Patient delay, interventions to minimize, 1338
- Percutaneous transluminal coronary angioplasty (PTCA). *See* Angioplasty, percutaneous transluminal coronary
- Perfusion. *See* Coronary perfusion; Myocardial perfusion imaging
- Pericardial tamponade, 1370
- Pericardiocentesis, 1359
- Pericarditis
in atrial fibrillation, 1363
chest pain from, 1335
focal, 1358
management of, in hospital, 1358-1359
- Personnel, for cost reduction, 1357
- Pharmacotherapy
for management of lipids, 1395-1396
for nicotine withdrawal, 1356
in non-ST-segment elevation cohort, 1353
prehospital, 1338
rationale and approach to, 1372
angiotensin-converting enzyme inhibitors, 1382-1383. *See also* Angiotensin-converting enzyme inhibitors
antiarrhythmics, 1380-1382. *See also* Antiarrhythmic agents
antithrombotics/anticoagulants, 1377-1380. *See also* Antithrombotics/Anticoagulants
aspirin and other platelet active drugs, 1373-1374. *See also* Aspirin; Platelet-active drugs
 β -adrenoreceptor blocking agents, 1381-1382. *See also* β -adrenergic blocking agents
calcium channel blockers, 1383-1384. *See also* Calcium channel blockers
inotropic agents, 1385t, 1385-1386. *See also* Inotropic agents

- magnesium, 1384, 1385. *See also* Magnesium nitroglycerin, 1372-1373. *See also* Nitroglycerin
thrombolytic therapy, 1374-1377. *See also* Thrombolytic therapy
- Phosphodiesterase inhibitors, 1385
- Physical activity, 1334
limiting of, 1354
- Plaque
fissuring or rupture of, 1374, 1377
rupture, 1393
- Plasmin, 1375
- Plasminogen activator (TPA), 1333, 1376, 1380
combined with heparin, 1376
comparison with other thrombolytic agents, 1375, 1375t, 1376
- Plasminogen molecule, single-chain, 1375
- Platelet(s), 1373. *See also* Antiplatelet agents
activation and aggregation, 1377, 1393
aspirin effects on, 1373
- Platelet-active drugs, 1373-1374. *See also* Antiplatelet agents
- Positron emission tomography (PET), 1389
- Potassium, repletion of, 1365
- PR segment
depression, 1358
displacement, 1363
- Practice guidelines, 1332-1333
executive summary of, 1333-1335
function of, 1333
- Practice patterns, variation in, 1357
- Prehospital issues related to acute myocardial infarction, 1333
emergency medical services systems, 1338-1339
intervention strategies, 1338
recognition and management, 1338
recommendations, 1337
thrombolysis, 1339-1340
- Preload, 1354, 1372
reduction of, 1372
in left ventricular dysfunction, 1359
in right ventricular infarction and dysfunction, 1360, 1361
- Premature ventricular complexes, 1381
- Pressure gradient, in right ventricular dysfunction, 1360
- Primary Angioplasty in Myocardial Infarction investigators. *See* PAMI
- Proarrhythmia, procainamide-related, 1381
- Procainamide, 1335, 1356, 1364
adverse effects, 1381
pharmacology, 1381
for ventricular tachycardia, 1364, 1365
- Procedures, changes in, 1337
- "Process of care," 1336
- Progesterins, 1399
- Propranolol, 1381
for secondary prevention, 1397
- Prourokinase, 1376
- Pseudoaneurysm, 1359
cardiac rupture and, 1359
- Psychological support, during hospitalization, 1356
- Public service personnel, training of, 1338-1339
- Pulmonary artery, oxygen saturation in, 1370
- Pulmonary artery wedge pressure, 1370
in right ventricular ischemia, 1360
- Pyrophosphate. *See* Technetium-99m pyrophosphate
- Q**
- Q wave, 1359, 1395
- Q wave myocardial infarction, 1345
- QRS complex, 1391
narrow, atropine for, 1344
- QT interval, prolonged, 1384
- Quinapril, 1383
- Quinidine, 1364
- R**
- Radi nuclide studies. *See also* Scintigraphy
- Radionuclide studies
in diagnosis of acute myocardial infarction, 1389
for discharge, 1335
- Rales, 1348
- Ramipril, 1383, 1397
- "Rebound effect," 1379
- Recurrent myocardial infarction, nondiagnostic ECG changes, 1353
- Refractory period, lengthening of, 1380
- Rehabilitation. *See* Cardiac rehabilitation
- Rehospitalization, 1353
- Reinfarction, 1358-1360, 1384
nifedipine effects on, 1383
PTCA and, compared with thrombolytic therapy, 1351
time factor in, 1334
verapamil effects on, 1384
- Reperfusion era, 1337
- Reperfusion therapy. *See also* Thrombolytic therapy
clinical markers of, 1393
early, 1333
indications for, 1337
prehospital, 1338
to reduce hospital stay, 1356
time delay in achieving, 1351
timing for, 1338
- Repolarization, 1354
- Respiratory depression, morphine-induced, 1355
- Restenosis, 1398
- Reteplase, 1376
- Revascularization, 1337
delays in, 1350
effect on clinical outcome, 1353
myocardial infarction during, 1395
patient selection for, 1335
in suspected myocardial infarction, 1353
use of heparin in, 1378
- Rhythm disturbances. *See also* Arrhythmias
atrial fibrillation, 1363-1364. *See also* Atrial fibrillation
bradyarrhythmias and heart block, 1366-1368. *See also* Bradyarrhythmias; Heart block
ventricular tachycardia/ventricular fibrillation, 1364-1365. *See also* Ventricular fibrillation; Ventricular tachycardia
- Right ventricular infarction and dysfunction, 1343, 1360, 1368
anatomic and physiologic considerations in, 1360
clinical diagnosis of, 1360, 1361
clinical presentation for, 1361
management of, 1361, 1361t
prognosis, 1361
- Risk factors, modification of, 1399
- Risk stratification, 1345, 1345f, 1346
for discharge from hospital, 1386, 1387, 1388-1389
in non-ST-segment elevation, 1352-1354
- "Rule out" MI, 1345
- Rupture. *See also under* Plaque
intraventricular septum, 1371
left ventricular free wall, 1371
ventricular, 1370
- S**
- Saline, normal, 1361
- Salvage procedures, PTCA for, compared with thrombolytic therapy, 1350
- Salvage procedures, thrombolytic therapy and, 1347
- Saphenous vein bypass graft, atherosclerosis in, 1395
- SAVE (Survival and Ventricular Enlargement) trial, 1397
- Scandinavian Simvastatin Survival Study, 1395
- SCATI study, 1378
- Scintigraphy. *See also* Radionuclide studies
pyrophosphate. *See* Technetium-99m pyrophosphate
stress, 1386, 1388
- Second International Study of Infarct Survival. *See* ISIS-2
- Second Leicester Intravenous Magnesium Intervention Trial trial. *See* LIMIT-2 trial
- Secondary prevention
angiotensin-converting enzyme inhibitors and, 1397
antiarrhythmic agents, 1399
anticoagulants, 1398
antioxidants, 1398
 β -adrenoceptor blockade, 1397-1398
calcium channel blockers, 1398
estrogen replacement therapy, 1399
long-term use of aspirin, 1397
management of lipids, 1395-1396
smoking cessation, 1395-1396
- Secondary Prevention Reinfarction Israeli Nifedipine Trial. *See* SPRINT
- Serum cardiac markers, 1334, 1340, 1346
measurement of, 1356
- Sestamibi. *See* Technetium-99m sestamibi
- Sexual activity, 1401
- Shock, cardiogenic, 1369
absence of, 1356
emergency or urgent coronary artery bypass graft surgery for, 1351
intra-aortic balloon counterpulsation in, 1362
intra-arterial pressure monitoring in, 1362
in left ventricular dysfunction, 1359-1360
in right ventricular infarction and dysfunction, 1360
treatment of, 1335
in ventricular septal defect, 1371
- SHOCK (Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock?) Registry, 1359-1360
- Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock? Registry. *See* SHOCK Registry
- Should We Intervene Following Thrombolysis? study. *See* SWIFT study
- Shunting, left-to-right, 1370
- Simvastatin, for secondary prevention, 1395
- Sinus bradycardia
atropine for, 1344
background, epidemiology and importance of, 1366
pacing for, 1367
treatment of, 1335, 1366
- Sinus tachycardia, 1348
- SMILE (Survival of Myocardial Infarction: Long Term Evaluation) study, 1382
- Smoking cessation, 1335, 1396
effects of, 1356
- Social integration, 1400
- Social support, 1400
- Sodium nitroprusside, 1362
for left ventricular dysfunction, 1359
- SOLVD (Studies of Left Ventricular Dysfunction) trial, 1397
- Sotalolol, 1364
- SPRINT (Secondary Prevention Reinfarction Israeli Nifedipine Trial), 1383

- ST-segment depression, 1352
 exercise-induced, mortality rates related to, 1387
 mortality rates associated with, effect of thrombolytic therapy on, 1353
elevation, 1333, 1334, 1337, 1340, 1377, 1378, 1387
 angiotensin-converting enzyme inhibitors for, 1382
 diagnostic and treatment measures for, 1350f
 early angiography in, 1351
 management of, 1345f, 1346
 mortality risk and, 1340, 1356, 1357f
 oxygen administration in, 1343
 in pericarditis, 1358
 in reinfarction, 1358
 in right ventricular ischemia, 1360
 thrombolytic therapy for, 1346, 1347, 1347f
- ST-T wave, in cardiac rupture, 1359
- Staff-patient ratios, 1357
- Staphylokinase, 1376
- Stenosis, 1356. *See also* Restenosis
 PTCA effects on, 1350
 PTCA in, 1393, 1394
 remodeling of, 1394
- Stool softeners, 1355
- Streptokinase (SK), 1350, 1375, 1376, 1380
 combined with
 alteplase, 1376
 aspirin, 1344, 1375
 heparin, 1376, 1377, 1378
 comparison with other thrombolytic agents, 1375, 1375t, 1376
 efficacy in acute myocardial infarction, 1375
 reuse of, 1376
 in ST-segment depression, 1352
- Stroke, 1334
 hemorrhagic, risk for, aspirin and, 1374
 PTCA and, compared with thrombolytic therapy, 1351
 rate of, effect of heparin on, 1378, 1379
 thrombolytic therapy-related, risk for, 1349, 1349f
- Studies of Left Ventricular Dysfunction trial. *See* SOLVD trial
- Stunning, 1388-1389
 right ventricular, 1360
- Sudden cardiac death
 aspirin effects on, 1396
 causes of, 1337
 occurrence of, 1355-1356
 risk for, 1338-1339, 1391
- Sulfinpyrazone, 1344, 1396
- Superoxide, production of, 1372
- Superoxide dismutase, 1398
- Surgery. *See also* specific procedure
 coronary artery graft. *See* Coronary artery artery graft surgery
 indications for, 1335
 for mechanical defects repair, 1368
 minimum operative caseload, 1371
 volume of, relation to outcome, 1371
- Survival and Ventricular Enlargement trial. *See* SAVE trial
- Survival of Myocardial Infarction: Long Term Evaluation study. *See* SMILE study
- SWIFT (Should We Intervene Following Thrombolysis?) study, 1394
- Sympathetic nervous system
 overactivity of, 1355
 stimulation, minimizing of, 1354
- Systolic dysfunction, 1335, 1392
 ACE inhibitors for, 1334
 right ventricular, 1360
 Systolic function, 1333
 digitalis effects on, 1386
 nitrate effects on, 1372
- T**
- T wave, in pericarditis, 1358
- Tachyarrhythmias, ventricular, 1368
 coronary artery bypass graft surgery for, 1369
- Tachycardia, 1339, 1343. *See also* Sinus tachycardia;
 Ventricular tachycardia
- TAMI (Thrombolysis and Angioplasty in Myocardial Infarction) trials, 1363, 1393, 1394
- Tamponade. *See also* Cardiac tamponade
 pericardial, 1370
- T-wave abnormalities, 1352
- Technetium-99m pyrophosphate, 1389
- Technetium-99m sestamibi, 1387, 1388, 1389
 in emergency department, 1346
 for infarct size measurement, 1389
- Tertiary centers, triage to, 1338
- Thallium-201 imaging, 1387, 1389
 in emergency department, 1346
- Thrombin, 1378
 clot-bound, 1377
 inhibition of, 1377
 by heparin, 1379
- Thrombolysis in Myocardial Infarction. *See* TIMI
- Thrombolytic therapy, 1333, 1336, 1337, 1340, 1352, 1359, 1383. *See also* Reperfusion therapy;
 specific agent
 for accelerated idioventricular rhythm, 1365
 ACE inhibitor use after, 1383
 adverse effects, 1333
 in atrial fibrillation, 1363
 background, 1374, 1375
 benefits in specific patient subgroups, 1376
 cardiac rupture from, 1359
 comparative efficacy, 1376
 compared with PTCA, 1350-1351
 comparison of agents, 1375, 1375t
 contraindications/cautions related to, 1345, 1348, 1349t
 coronary angiography and possible percutaneous transluminal coronary angioplasty after, 1392
 coronary artery bypass graft surgery after, 1369
 current use rates for, 1377
 decision for, influences on, 1347, 1347f, 1348
 early, 1350
 effect on mortality rate, 1333
 effect on outcome in nondiagnostic electrocardiographic changes, 1352
 exercise testing and, 1387
 failed, coronary angiography and percutaneous transluminal coronary angioplasty after, 1392-1393
 general mechanism of action and pharmacological properties, 1375
 heparin administration after, 1334
 indications for, 1345
 with intra-aortic balloon pump, 1363
 intravenous, efficacy in acute myocardial infarction, 1375
 in ischemic-type chest discomfort, 1353
 mortality rates and, 1387
 ST-segment depression and, 1352
 ST-segment elevation and, 1352
 net clinical benefit of, 1348
 in nondiagnostic ECG changes, 1353
 prehospital-initiated, 1339-1340
 "door-to-door" needle time, 1339
 outcome associated with, 1339
 primary PTCA as alternative to, 1350
 recommendations, 1346-1349
 regimens, recommendations for selecting, 1376
 in right ventricular ischemia/infarction, 1361
 risk of stroke and, 1348, 1349f
 successful, routine coronary angiography and percutaneous transluminal coronary angioplasty after, 1394
 time-dependent benefits of, 1337
 timing of, 1333
 use of heparin in, 1379
- Thrombosis, thrombus, 1373, 1376
 arterial, 1362
 formation of, 1377
 mural, 1334
 occlusive, 1393
 prevention of, role of aspirin in, 1373-1374
 recurrent, discontinuation of heparin and, 1379
- Thromboxane A₂, production of, aspirin effects on, 1344
- Ticlopidine, 1344, 1396
 action of, 1374
- Time factors, related to recognition and management of myocardial infarction, 1338, 1339
 "door-to-door" needle time, 1339
- TIMI (Thrombolysis in Myocardial Infarction) flow rates, 1350
- TIMI-II trial, 1369, 1382
- TIMI-IIB trial, 1394
- TIMI-IIIB trial, 1353, 1354
- TIMI-9B trial, 1380
- Timolol, for secondary prevention, 1397
- Tissue plasminogen activator. *See* Plasminogen activator
- TNK-plasminogen activator, 1376
- Tomography. *See also* Computed tomography
 positron emission, 1389
- Torsade de pointes, 1381, 1384
- TRACE (Trandolapril Cardiac Evaluation) trial, 1397
- Trandolapril, 1397
- Trandolapril Cardiac Evaluation trial. *See* TRACE trial
- Transmural myocardial infarction, pericarditis in, 1358
- Transmural necrosis, 1374
- Transplantation. *See* Cardiac transplantation
- Transport times, 1338, 1339
- Transportation, emergency, 1338
- Treadmill testing, prediction of mortality and, 1391
- Treatment of myocardial infarction
 changes in, 1337
 prehospital, 1333
 seeking of, patient delay in, 1338
 timing of, 1338, 1339
- TRENT (Trial of Early Nifedipine Treatment in Acute Myocardial Infarction), 1383
- Triage, 1338, 1339, 1340, 1357
- Trial of Early Nifedipine Treatment in Acute Myocardial Infarction. *See* TRENT
- Troponin I (cTnI), 1334, 1341, 1354, 1356
- Troponin T (cTnT), 1334, 1341, 1356
- U**
- Unstable ischemic syndromes, 1362
- Urokinase, use of heparin with, 1377, 1378
- V**
- V wave, 1370
- Vagal tone, decreased, 1391
- Valsalva maneuver, avoidance of, 1354

- Vascular endothelium, ACE inhibitors arising from, 1397
- Vasoconstriction, 1343, 1372
peripheral, 1354
- Vasoconstrictors, inotropic agents, 1385
- Vasodilation, vasodilators, 1362
nitrates, 1371-1372
with nitroglycerin, 1343
- Vaughan-Williams classes, 1380, 1381
- Venous access, peripheral, 1342
- Ventilation
mechanical, 1343
morphine effects on, 1355
- Ventilation-perfusion mismatch, 1343
- Ventricular arrhythmias. *See* Arrhythmias, ventricular
- Ventricular asystole, 1366
atropine for, 1344
- Ventricular capture, loss of, 1368
- Ventricular ectopy, 1391
lidocaine for, 1381
- Ventricular fibrillation (VF), 1364, 1381
amiodarone for, 1381
background, 1364-1365
bretylum for, 1380
defibrillation shocks for, 1339
early sustained, absence of, 1356
ischemia-induced, 1338-1339
lidocaine for, 1381
management strategies for, 1365
primary, 1364-1366
procainamide for, 1381
secondary, 1364
sustained, 1365
treatment of, 1335
- Ventricular filling, shifts in, 1354
- Ventricular function. *See also* Left ventricular function; Right ventricular infarction and dysfunction
impairment of, ACE inhibitors for, 1334
- Ventricular premature beats, 1364, 1391
- Ventricular rate, in atrial fibrillation, 1363
- Ventricular response, rapid, 1383
- Ventricular rupture, 1370
- Ventricular septal defect (VSD), postinfarction, 1370
management of, 1371
emergency or urgent coronary artery bypass graft surgery for, 1351
- Ventricular tachycardia (VT), 1356, 1364, 1381
amiodarone for, 1381
background, 1365
bretylum for, 1380-1381
early sustained, absence of, 1356
lidocaine for, 1381
management strategies for, 1365
monomorphic, 1335, 1364, 1365, 1366
sustained, 1391
nonsustained, 1365, 1391
polymorphic, 1364, 1365, 1366
procainamide for, 1381
- Verapamil, 1384
for atrial fibrillation, 1363
contraindications to, 1383
pharmacology, 1383-1384
- Veterans Administration Cooperative Study, 1374
- Viability. *See* Myocardial viability
- Vitamin E, 1398
- Volume
depletion, 1385
expansion, 1335
loading, in right ventricular ischemia/infarction, 1361
- W**
- Walking, 1401
- Warfarin, for secondary prevention, 1398
- Water. *See also* Fluid
lung, excessive, 1343
- Weight, 1335, 1349
- Women
estrogen replacement therapy for, 1399
symptoms of acute myocardial infarction in, 1340
- Work, return to, 1401
- World Health Organization (WHO), 1340, 1341
- Writing groups, 1332-1333
- Z**
- Zofenopril, 1383